Clinical Course and Prognosis of Smoldering (Asymptomatic) Multiple Myeloma
In this study, the risk of progression of asymptomatic smoldering multiple myeloma to active multiple myeloma was found to be related to the level of serum monoclonal immunoglobulin and the proportion of plasma cells in the bone marrow at the time of diagnosis. The risk of progression of smoldering...
Gespeichert in:
| Veröffentlicht in: | The New England journal of medicine 2007-06, Vol.356 (25), p.2582-2590 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 2590 |
|---|---|
| container_issue | 25 |
| container_start_page | 2582 |
| container_title | The New England journal of medicine |
| container_volume | 356 |
| creator | Kyle, Robert A Remstein, Ellen D Therneau, Terry M Dispenzieri, Angela Kurtin, Paul J Hodnefield, Janice M Larson, Dirk R Plevak, Matthew F Jelinek, Diane F Fonseca, Rafael Melton, Lee Joseph Rajkumar, S. Vincent |
| description | In this study, the risk of progression of asymptomatic smoldering multiple myeloma to active multiple myeloma was found to be related to the level of serum monoclonal immunoglobulin and the proportion of plasma cells in the bone marrow at the time of diagnosis.
The risk of progression of smoldering multiple myeloma to active multiple myeloma was found to be related to the level of serum monoclonal immunoglobulin and the proportion of plasma cells in the bone marrow at the time of diagnosis.
Smoldering multiple myeloma is an asymptomatic proliferative disorder of plasma cells with a high risk of progression to symptomatic, or active, multiple myeloma. Previous studies have used various definitions of the disease, and this variability has resulted in important differences in the reported clinical course of the disease.
1
–
7
International consensus criteria for smoldering multiple myeloma were adopted recently to rectify this problem.
8
We report here on the prognosis and risk factors for progression of smoldering multiple myeloma in a large cohort of patients for whom long-term follow-up data were available and in whom the disease was defined with the . . . |
| doi_str_mv | 10.1056/NEJMoa070389 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_70649557</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>20407298</sourcerecordid><originalsourceid>FETCH-LOGICAL-c644t-daf867cc7f006efd38eaf757be926f33292cc1e615104d79a65498f90e5b88bb3</originalsourceid><addsrcrecordid>eNqF0c1rFDEYBvAgFrut3jzLIFYUHH3znRzLUq3aVUE9D5lMUrJkJmsyc9j_3pRdqIhgLi-EH0_I-yD0FMNbDFy8-3L1aZMMSKBKP0ArzCltGQPxEK0AiGqZ1PQUnZWyhXow04_QKZZcERBqhT6vY5iCNbFZpyUX15hpaL7ldDulEkqTfPN9THFwOUy3zavLsh93cxrNHOzrZrPEOeyiazZ7F-vlY3TiTSzuyXGeo5_vr36sr9ubrx8-ri9vWisYm9vBeCWktdIDCOcHqpzxksveaSI8pUQTa7ETmGNgg9RGcKaV1-B4r1Tf03P08pC7y-nX4srcjaFYF6OZXFpKJ0Ewzbn8LyTAQBKtKnz-F9zWbUz1Ex0hVBMgWFf05oBsTqVk57tdDqPJ-w5Dd1dF92cVlT87Zi796IZ7fNx9BRdHYEotwGcz2VDunVKMCHoX9OLgxrF0k9uO_37vN0ifmvM</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>223920219</pqid></control><display><type>article</type><title>Clinical Course and Prognosis of Smoldering (Asymptomatic) Multiple Myeloma</title><source>MEDLINE</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>New England Journal of Medicine</source><creator>Kyle, Robert A ; Remstein, Ellen D ; Therneau, Terry M ; Dispenzieri, Angela ; Kurtin, Paul J ; Hodnefield, Janice M ; Larson, Dirk R ; Plevak, Matthew F ; Jelinek, Diane F ; Fonseca, Rafael ; Melton, Lee Joseph ; Rajkumar, S. Vincent</creator><creatorcontrib>Kyle, Robert A ; Remstein, Ellen D ; Therneau, Terry M ; Dispenzieri, Angela ; Kurtin, Paul J ; Hodnefield, Janice M ; Larson, Dirk R ; Plevak, Matthew F ; Jelinek, Diane F ; Fonseca, Rafael ; Melton, Lee Joseph ; Rajkumar, S. Vincent</creatorcontrib><description>In this study, the risk of progression of asymptomatic smoldering multiple myeloma to active multiple myeloma was found to be related to the level of serum monoclonal immunoglobulin and the proportion of plasma cells in the bone marrow at the time of diagnosis.
The risk of progression of smoldering multiple myeloma to active multiple myeloma was found to be related to the level of serum monoclonal immunoglobulin and the proportion of plasma cells in the bone marrow at the time of diagnosis.
Smoldering multiple myeloma is an asymptomatic proliferative disorder of plasma cells with a high risk of progression to symptomatic, or active, multiple myeloma. Previous studies have used various definitions of the disease, and this variability has resulted in important differences in the reported clinical course of the disease.
1
–
7
International consensus criteria for smoldering multiple myeloma were adopted recently to rectify this problem.
8
We report here on the prognosis and risk factors for progression of smoldering multiple myeloma in a large cohort of patients for whom long-term follow-up data were available and in whom the disease was defined with the . . .</description><identifier>ISSN: 0028-4793</identifier><identifier>EISSN: 1533-4406</identifier><identifier>DOI: 10.1056/NEJMoa070389</identifier><identifier>PMID: 17582068</identifier><identifier>CODEN: NEJMAG</identifier><language>eng</language><publisher>Boston, MA: Massachusetts Medical Society</publisher><subject>Adult ; Aged ; Aged, 80 and over ; Amyloidosis ; Antibodies, Monoclonal - blood ; Biological and medical sciences ; Biopsy ; Bone marrow ; Bone Marrow Cells - immunology ; Bone Marrow Cells - pathology ; Bone Marrow Examination ; Cellulose acetate ; Cohort Studies ; Disease Progression ; Estimates ; Female ; General aspects ; Humans ; Immunodeficiencies. Immunoglobulinopathies ; Immunoglobulinopathies ; Immunopathology ; Lymphocyte Count ; Male ; Medical sciences ; Middle Aged ; Multiple Myeloma - blood ; Multiple Myeloma - immunology ; Multiple Myeloma - pathology ; Plasma Cells ; Prognosis ; Proteins ; Risk Factors ; Transplants & implants</subject><ispartof>The New England journal of medicine, 2007-06, Vol.356 (25), p.2582-2590</ispartof><rights>Copyright © 2007 Massachusetts Medical Society. All rights reserved.</rights><rights>2007 INIST-CNRS</rights><rights>Copyright 2007 Massachusetts Medical Society.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c644t-daf867cc7f006efd38eaf757be926f33292cc1e615104d79a65498f90e5b88bb3</citedby><cites>FETCH-LOGICAL-c644t-daf867cc7f006efd38eaf757be926f33292cc1e615104d79a65498f90e5b88bb3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.nejm.org/doi/pdf/10.1056/NEJMoa070389$$EPDF$$P50$$Gmms$$H</linktopdf><linktohtml>$$Uhttps://www.nejm.org/doi/full/10.1056/NEJMoa070389$$EHTML$$P50$$Gmms$$H</linktohtml><link.rule.ids>314,776,780,2746,2747,26080,27901,27902,52357,54039</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=18842639$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/17582068$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Kyle, Robert A</creatorcontrib><creatorcontrib>Remstein, Ellen D</creatorcontrib><creatorcontrib>Therneau, Terry M</creatorcontrib><creatorcontrib>Dispenzieri, Angela</creatorcontrib><creatorcontrib>Kurtin, Paul J</creatorcontrib><creatorcontrib>Hodnefield, Janice M</creatorcontrib><creatorcontrib>Larson, Dirk R</creatorcontrib><creatorcontrib>Plevak, Matthew F</creatorcontrib><creatorcontrib>Jelinek, Diane F</creatorcontrib><creatorcontrib>Fonseca, Rafael</creatorcontrib><creatorcontrib>Melton, Lee Joseph</creatorcontrib><creatorcontrib>Rajkumar, S. Vincent</creatorcontrib><title>Clinical Course and Prognosis of Smoldering (Asymptomatic) Multiple Myeloma</title><title>The New England journal of medicine</title><addtitle>N Engl J Med</addtitle><description>In this study, the risk of progression of asymptomatic smoldering multiple myeloma to active multiple myeloma was found to be related to the level of serum monoclonal immunoglobulin and the proportion of plasma cells in the bone marrow at the time of diagnosis.
The risk of progression of smoldering multiple myeloma to active multiple myeloma was found to be related to the level of serum monoclonal immunoglobulin and the proportion of plasma cells in the bone marrow at the time of diagnosis.
Smoldering multiple myeloma is an asymptomatic proliferative disorder of plasma cells with a high risk of progression to symptomatic, or active, multiple myeloma. Previous studies have used various definitions of the disease, and this variability has resulted in important differences in the reported clinical course of the disease.
1
–
7
International consensus criteria for smoldering multiple myeloma were adopted recently to rectify this problem.
8
We report here on the prognosis and risk factors for progression of smoldering multiple myeloma in a large cohort of patients for whom long-term follow-up data were available and in whom the disease was defined with the . . .</description><subject>Adult</subject><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Amyloidosis</subject><subject>Antibodies, Monoclonal - blood</subject><subject>Biological and medical sciences</subject><subject>Biopsy</subject><subject>Bone marrow</subject><subject>Bone Marrow Cells - immunology</subject><subject>Bone Marrow Cells - pathology</subject><subject>Bone Marrow Examination</subject><subject>Cellulose acetate</subject><subject>Cohort Studies</subject><subject>Disease Progression</subject><subject>Estimates</subject><subject>Female</subject><subject>General aspects</subject><subject>Humans</subject><subject>Immunodeficiencies. Immunoglobulinopathies</subject><subject>Immunoglobulinopathies</subject><subject>Immunopathology</subject><subject>Lymphocyte Count</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Multiple Myeloma - blood</subject><subject>Multiple Myeloma - immunology</subject><subject>Multiple Myeloma - pathology</subject><subject>Plasma Cells</subject><subject>Prognosis</subject><subject>Proteins</subject><subject>Risk Factors</subject><subject>Transplants & implants</subject><issn>0028-4793</issn><issn>1533-4406</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2007</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>BEC</sourceid><sourceid>BENPR</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNqF0c1rFDEYBvAgFrut3jzLIFYUHH3znRzLUq3aVUE9D5lMUrJkJmsyc9j_3pRdqIhgLi-EH0_I-yD0FMNbDFy8-3L1aZMMSKBKP0ArzCltGQPxEK0AiGqZ1PQUnZWyhXow04_QKZZcERBqhT6vY5iCNbFZpyUX15hpaL7ldDulEkqTfPN9THFwOUy3zavLsh93cxrNHOzrZrPEOeyiazZ7F-vlY3TiTSzuyXGeo5_vr36sr9ubrx8-ri9vWisYm9vBeCWktdIDCOcHqpzxksveaSI8pUQTa7ETmGNgg9RGcKaV1-B4r1Tf03P08pC7y-nX4srcjaFYF6OZXFpKJ0Ewzbn8LyTAQBKtKnz-F9zWbUz1Ex0hVBMgWFf05oBsTqVk57tdDqPJ-w5Dd1dF92cVlT87Zi796IZ7fNx9BRdHYEotwGcz2VDunVKMCHoX9OLgxrF0k9uO_37vN0ifmvM</recordid><startdate>20070621</startdate><enddate>20070621</enddate><creator>Kyle, Robert A</creator><creator>Remstein, Ellen D</creator><creator>Therneau, Terry M</creator><creator>Dispenzieri, Angela</creator><creator>Kurtin, Paul J</creator><creator>Hodnefield, Janice M</creator><creator>Larson, Dirk R</creator><creator>Plevak, Matthew F</creator><creator>Jelinek, Diane F</creator><creator>Fonseca, Rafael</creator><creator>Melton, Lee Joseph</creator><creator>Rajkumar, S. Vincent</creator><general>Massachusetts Medical Society</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>0TZ</scope><scope>7RV</scope><scope>7X7</scope><scope>7XB</scope><scope>8AO</scope><scope>8C1</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AN0</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BEC</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>HCIFZ</scope><scope>K0Y</scope><scope>LK8</scope><scope>M0R</scope><scope>M0T</scope><scope>M1P</scope><scope>M2M</scope><scope>M2O</scope><scope>M2P</scope><scope>M7P</scope><scope>MBDVC</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>PSYQQ</scope><scope>Q9U</scope><scope>7T5</scope><scope>H94</scope><scope>7X8</scope></search><sort><creationdate>20070621</creationdate><title>Clinical Course and Prognosis of Smoldering (Asymptomatic) Multiple Myeloma</title><author>Kyle, Robert A ; Remstein, Ellen D ; Therneau, Terry M ; Dispenzieri, Angela ; Kurtin, Paul J ; Hodnefield, Janice M ; Larson, Dirk R ; Plevak, Matthew F ; Jelinek, Diane F ; Fonseca, Rafael ; Melton, Lee Joseph ; Rajkumar, S. Vincent</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c644t-daf867cc7f006efd38eaf757be926f33292cc1e615104d79a65498f90e5b88bb3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2007</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Amyloidosis</topic><topic>Antibodies, Monoclonal - blood</topic><topic>Biological and medical sciences</topic><topic>Biopsy</topic><topic>Bone marrow</topic><topic>Bone Marrow Cells - immunology</topic><topic>Bone Marrow Cells - pathology</topic><topic>Bone Marrow Examination</topic><topic>Cellulose acetate</topic><topic>Cohort Studies</topic><topic>Disease Progression</topic><topic>Estimates</topic><topic>Female</topic><topic>General aspects</topic><topic>Humans</topic><topic>Immunodeficiencies. Immunoglobulinopathies</topic><topic>Immunoglobulinopathies</topic><topic>Immunopathology</topic><topic>Lymphocyte Count</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Multiple Myeloma - blood</topic><topic>Multiple Myeloma - immunology</topic><topic>Multiple Myeloma - pathology</topic><topic>Plasma Cells</topic><topic>Prognosis</topic><topic>Proteins</topic><topic>Risk Factors</topic><topic>Transplants & implants</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Kyle, Robert A</creatorcontrib><creatorcontrib>Remstein, Ellen D</creatorcontrib><creatorcontrib>Therneau, Terry M</creatorcontrib><creatorcontrib>Dispenzieri, Angela</creatorcontrib><creatorcontrib>Kurtin, Paul J</creatorcontrib><creatorcontrib>Hodnefield, Janice M</creatorcontrib><creatorcontrib>Larson, Dirk R</creatorcontrib><creatorcontrib>Plevak, Matthew F</creatorcontrib><creatorcontrib>Jelinek, Diane F</creatorcontrib><creatorcontrib>Fonseca, Rafael</creatorcontrib><creatorcontrib>Melton, Lee Joseph</creatorcontrib><creatorcontrib>Rajkumar, S. Vincent</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Pharma and Biotech Premium PRO</collection><collection>Proquest Nursing & Allied Health Source</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>British Nursing Database</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>eLibrary</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>SciTech Premium Collection</collection><collection>New England Journal of Medicine</collection><collection>ProQuest Biological Science Collection</collection><collection>Consumer Health Database</collection><collection>Healthcare Administration Database</collection><collection>Medical Database</collection><collection>Psychology Database (ProQuest)</collection><collection>Research Library</collection><collection>Science Database</collection><collection>Biological Science Database</collection><collection>Research Library (Corporate)</collection><collection>Nursing & Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest One Psychology</collection><collection>ProQuest Central Basic</collection><collection>Immunology Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>The New England journal of medicine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Kyle, Robert A</au><au>Remstein, Ellen D</au><au>Therneau, Terry M</au><au>Dispenzieri, Angela</au><au>Kurtin, Paul J</au><au>Hodnefield, Janice M</au><au>Larson, Dirk R</au><au>Plevak, Matthew F</au><au>Jelinek, Diane F</au><au>Fonseca, Rafael</au><au>Melton, Lee Joseph</au><au>Rajkumar, S. Vincent</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Clinical Course and Prognosis of Smoldering (Asymptomatic) Multiple Myeloma</atitle><jtitle>The New England journal of medicine</jtitle><addtitle>N Engl J Med</addtitle><date>2007-06-21</date><risdate>2007</risdate><volume>356</volume><issue>25</issue><spage>2582</spage><epage>2590</epage><pages>2582-2590</pages><issn>0028-4793</issn><eissn>1533-4406</eissn><coden>NEJMAG</coden><abstract>In this study, the risk of progression of asymptomatic smoldering multiple myeloma to active multiple myeloma was found to be related to the level of serum monoclonal immunoglobulin and the proportion of plasma cells in the bone marrow at the time of diagnosis.
The risk of progression of smoldering multiple myeloma to active multiple myeloma was found to be related to the level of serum monoclonal immunoglobulin and the proportion of plasma cells in the bone marrow at the time of diagnosis.
Smoldering multiple myeloma is an asymptomatic proliferative disorder of plasma cells with a high risk of progression to symptomatic, or active, multiple myeloma. Previous studies have used various definitions of the disease, and this variability has resulted in important differences in the reported clinical course of the disease.
1
–
7
International consensus criteria for smoldering multiple myeloma were adopted recently to rectify this problem.
8
We report here on the prognosis and risk factors for progression of smoldering multiple myeloma in a large cohort of patients for whom long-term follow-up data were available and in whom the disease was defined with the . . .</abstract><cop>Boston, MA</cop><pub>Massachusetts Medical Society</pub><pmid>17582068</pmid><doi>10.1056/NEJMoa070389</doi><tpages>9</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0028-4793 |
| ispartof | The New England journal of medicine, 2007-06, Vol.356 (25), p.2582-2590 |
| issn | 0028-4793 1533-4406 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_70649557 |
| source | MEDLINE; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; New England Journal of Medicine |
| subjects | Adult Aged Aged, 80 and over Amyloidosis Antibodies, Monoclonal - blood Biological and medical sciences Biopsy Bone marrow Bone Marrow Cells - immunology Bone Marrow Cells - pathology Bone Marrow Examination Cellulose acetate Cohort Studies Disease Progression Estimates Female General aspects Humans Immunodeficiencies. Immunoglobulinopathies Immunoglobulinopathies Immunopathology Lymphocyte Count Male Medical sciences Middle Aged Multiple Myeloma - blood Multiple Myeloma - immunology Multiple Myeloma - pathology Plasma Cells Prognosis Proteins Risk Factors Transplants & implants |
| title | Clinical Course and Prognosis of Smoldering (Asymptomatic) Multiple Myeloma |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-01T03%3A53%3A00IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Clinical%20Course%20and%20Prognosis%20of%20Smoldering%20(Asymptomatic)%20Multiple%20Myeloma&rft.jtitle=The%20New%20England%20journal%20of%20medicine&rft.au=Kyle,%20Robert%20A&rft.date=2007-06-21&rft.volume=356&rft.issue=25&rft.spage=2582&rft.epage=2590&rft.pages=2582-2590&rft.issn=0028-4793&rft.eissn=1533-4406&rft.coden=NEJMAG&rft_id=info:doi/10.1056/NEJMoa070389&rft_dat=%3Cproquest_cross%3E20407298%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=223920219&rft_id=info:pmid/17582068&rfr_iscdi=true |